A detailed history of Guggenheim Capital LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Guggenheim Capital LLC holds 50,938 shares of ADPT stock, worth $394,769. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,938
Previous 53,328 4.48%
Holding current value
$394,769
Previous $193,000 34.72%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.37 - $5.12 $8,054 - $12,236
-2,390 Reduced 4.48%
50,938 $260,000
Q2 2024

Aug 14, 2024

SELL
$2.34 - $3.96 $3,619 - $6,126
-1,547 Reduced 2.82%
53,328 $193,000
Q1 2024

May 14, 2024

SELL
$2.88 - $4.8 $5,685 - $9,475
-1,974 Reduced 3.47%
54,875 $176,000
Q4 2023

Feb 14, 2024

SELL
$3.46 - $5.33 $1,214 - $1,870
-351 Reduced 0.61%
56,849 $278,000
Q3 2023

Nov 14, 2023

BUY
$5.07 - $8.44 $155,922 - $259,563
30,754 Added 116.29%
57,200 $311,000
Q2 2023

Aug 11, 2023

BUY
$6.19 - $8.78 $94,744 - $134,386
15,306 Added 137.4%
26,446 $177,000
Q1 2023

May 10, 2023

BUY
$7.8 - $10.11 $86,892 - $112,625
11,140 New
11,140 $98,000
Q3 2022

Nov 14, 2022

SELL
$6.5 - $12.67 $6,357 - $12,391
-978 Reduced 4.99%
18,605 $132,000
Q2 2022

Aug 15, 2022

BUY
$6.4 - $14.73 $5,632 - $12,962
880 Added 4.71%
19,583 $158,000
Q1 2022

May 16, 2022

BUY
$10.12 - $28.9 $688 - $1,965
68 Added 0.36%
18,703 $260,000
Q4 2021

Feb 14, 2022

SELL
$25.17 - $36.85 $1.32 Million - $1.93 Million
-52,384 Reduced 73.76%
18,635 $523,000
Q3 2021

Nov 15, 2021

SELL
$30.02 - $39.87 $85,466 - $113,509
-2,847 Reduced 3.85%
71,019 $2.41 Million
Q2 2021

Aug 13, 2021

BUY
$32.22 - $44.59 $26,098 - $36,117
810 Added 1.11%
73,866 $3.02 Million
Q1 2021

May 13, 2021

BUY
$37.26 - $67.74 $638,338 - $1.16 Million
17,132 Added 30.63%
73,056 $2.94 Million
Q4 2020

Feb 16, 2021

BUY
$45.01 - $65.47 $2.52 Million - $3.66 Million
55,924 New
55,924 $3.31 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $1.11B
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.